← Back to Search

Procedure

Ablation for Liver Cancer

N/A

Waitlist Available

Led By Constantinos Sofocleous, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients diagnosed with secondary hepatic malignancy

Patients with confined liver disease or stable limited extrahepatic disease

Must not have

Patients < 18 years old

Less than 5 mm distance of the tumor margin from a major vessel >7mm in diameter

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is to study whether a particular test can show if the ablation worked in treating the tumor.

Who is the study for?

This trial is for adults with liver tumors no larger than 5cm, who aren't surgical candidates or prefer not to have surgery. They should have a stable blood clotting measure (INR<1.5), enough platelets, and either confined liver disease or limited stable disease outside the liver.

What is being tested?

The study tests if analyzing tissue from ablated malignant liver metastases can predict treatment success. It involves CT-guided percutaneous ablation—a minimally invasive procedure—and examines whether new growths are cancerous post-treatment.

What are the potential side effects?

While specific side effects are not listed here, percutaneous ablation procedures may include risks such as pain at the site of treatment, bleeding, infection, and damage to nearby organs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with cancer that has spread to my liver.

Select...

My cancer is mainly in my liver or is stable and not widely spread.

Select...

My cancer lesion is 5cm or smaller.

Select...

I am choosing a non-surgical treatment option instead of surgery.

Select...

My blood clotting time is within a safe range for a procedure.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 18 years old.

Select...

My tumor is very close to a large blood vessel.

Select...

My tumor is very close to a vital organ and cannot be safely treated with certain techniques.

Select...

My INR is above 1.5 and cannot be corrected with treatments.

Select...

My platelet count is below 50,000 and cannot be increased with a transfusion.

Select...

I have had more than 3 tumors treated without surgery.

Select...

I have cancer spread to more than 5 areas outside the liver.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Tumor response

Secondary study objectives

Duration of treatment response

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: CT guided percutaneous ablationExperimental Treatment1 Intervention

The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.

0 / 12Eligibility criteria met